Alumis Inc
PublicAlumis Inc is now publicly traded
The data on this page reflects Alumis Inc's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Jun 27, 2024
Last Round
Follow-on Offering
Jan 9, 2026
Est. Valuation at Exit
$1.65B
Total Funding Raised
$1.12B
Company Overview
Alumis Inc is a clinical-stage biopharmaceutical company that develops oral small-molecule therapies for immune-mediated and neuroinflammatory diseases.
Sector
Biotech
AI Layer
Non-AI
Keywords
Alumis Inc Comparables
Compare Alumis Inc with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Reistone Biopharma | 78% | |
| 杭州高光制药股份有限公司 | 74% | |
| Lynk Pharmaceuticals | 73% |
For institutional investors. Book with your work email.
Alumis Inc Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Jan 9, 2026 | ||||
| M&A | May 21, 2025 | ||||
| IPO | Jun 27, 2024 | ||||
| Series C | Mar 6, 2024 | ||||
| Series B | Jan 6, 2022 | ||||
Series A | May 5, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Alumis Inc Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Omega Funds | Series C |
| Guggenheim Securities | IPO |
| Ally Bridge Group | Series C |
| Heartland Healthcare Capital | Series C |
| Cormorant Asset Management | Series C |
| Cormorant Capital | Series C |
| Morgan Stanley | IPO |
For institutional investors. Book with your work email.
Alumis Inc Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.